Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN)
Benlysta (belimumab) requires prior authorization for active systemic lupus erythematosus (SLE) and active lupus nephritis (LN). Lupkynis (voclosporin) and Saphnelo (anifrolumab-fnia) are considered not medically necessary because other formulary alternatives are covered by the plan for these conditions. The most recent review, dated 02/24/2026, revised the medically necessary criteria for members with active SLE without active lupus nephritis.